This study compares the impact of the 3 different out-of-pocket maximums proposed in Congress and by the Medicare Payment Advisory Commission.
Sonal Parasrampuria, PhD, MPH
Advertisement
Articles by Sonal Parasrampuria, PhD, MPH
Out-of-pocket (OOP) spending for specialty drugs is substantially higher in Medicare Part D compared with employer-sponsored insurance because of the Part D benefit design.
Advertisement
Latest Updated Articles
- Effects of an Out-of-Pocket Maximum in Medicare Part D
February 7th 2022
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the FDA's Peptide Reversal
2
US Employer Health Care Costs Projected to Rise 9.5% in 2027
3
Student Mental Health, Success Tied to Future Health and Affordability
4
FDA Approves First Orexin Agonist for Narcolepsy Type 1
5